NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
01/02/2020
Voltar para busca
Dado oficial do USPTO
ETHYPHARM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
07/04/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
21/04/2008
Data de registro
23/06/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/02/2020
Última transação
07/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
1999-07-00
Primeiro uso no comércio
1999-07-00
Código do desenho
4
Tipo de titular
99
Localização do titular
Saint Cloud, FR
Examinador
BENJAMIN, SARA NICOLE
Unidade examinadora
M10
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
Ethypharm, S.A.
Ethypharm, S.A.
Representantes
CATHLEEN E. STADECKER, DOWNS RACHLIN MARTIN PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; excipients, namely, drug delivery agents consisting of compounds that facilitate the delivery a wide range of pharmaceuticals; veterinary pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; sanitary pharmaceutical products for medical purposes, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases; dietetic substances adopted for medical use; all purpose disinfectants; chemical, biological and biochemical pharmaceutical products for medical and veterinary use, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases
Classe 42
Medical studies and clinical studies, namely, scientific research services for medical purposes; research and development of new products for third parties in the medical and pharmaceutical field; engineering services in the medical and pharmaceutical field; chemical research; chemical analyses
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
01/02/2020
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
01/02/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/02/2020
E89R
TEAS SECTION 8 & 9 RECEIVED
18/12/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
23/06/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
03/11/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/11/2016
ES7R
TEAS SECTION 7 REQUEST RECEIVED
02/11/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
27/10/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/10/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/10/2016
REIN
REINSTATED
26/10/2016
C8..
CANCELLED SEC. 8 (6-YR)
04/10/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
04/03/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
17/07/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
16/07/2015
E815
TEAS SECTION 8 & 15 RECEIVED
23/06/2015
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS NOT UPDATED
25/09/2012
PAPER RECEIVED
13/09/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
23/06/2009
PUBO
PUBLISHED FOR OPPOSITION
07/04/2009
NPUB
NOTICE OF PUBLICATION
18/03/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/03/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/02/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
27/02/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/02/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
27/02/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/02/2009
ACEC
AMENDMENT FROM APPLICANT ENTERED
05/02/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2009
ALIE
ASSIGNED TO LIE
05/02/2009
PAPER RECEIVED
03/02/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/08/2008
GNRT
NON-FINAL ACTION E-MAILED
06/08/2008
CNRT
NON-FINAL ACTION WRITTEN
06/08/2008
DOCK
ASSIGNED TO EXAMINER
05/08/2008
MPMK
NOTICE OF PSEUDO MARK MAILED
25/04/2008
NWAP
NEW APPLICATION ENTERED
24/04/2008
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ETHYPHARM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.